Dear Ambry Genetics Customer,

We are committed to providing the highest quality genetic testing and results for our customers and their patients. After careful consideration, we have decided to discontinue AmbryScore to help reduce disparities in access to genetic testing and to stay aligned with current guidelines.

Due to limited data across ethnic populations, most polygenic risk scores, including AmbryScore, have not been validated for use in patients of diverse backgrounds. Additionally, in September of 2020, the National Comprehensive Cancer Network (NCCN) updated its guidelines advising against use of polygenic risk scores in routine patient management but recommended them in clinical trial settings.

Regular review of expert consensus guidelines and scientific literature helps us ensure our products and services meet the most up-to-date standards in science and clinical management represented across broader populations. 

Effective May 20th, 2021, AmbryScore (Breast and Prostate) will be removed from our testing menu until polygenic risk scores have been integrated into guidelines for use in clinical management and redeveloped as a pan-ethnic resource. We will continue to engage in research collaborations to contribute to the growing body of literature related to polygenic risk scores, including validation of pan-ethnic testing options.

If you have any questions or concerns, please do not hesitate to contact your local representative or client services (Email: info@ambrygen.com; Tel: +1 949-900-5500).

Best Regards,

The Ambry Product Team